Showing 136-140 of 152 real-world data & outcomes research:
New Harmonized Outcome Measures for Atrial Fibrillation Published in HeartRhythm

November 15, 2018 —OM1, a leading health outcomes and technology company, today announced the publication of new harmonized outcome measures for atrial fibrillation (AF) in HeartRhythm.  OM1’s Richard Gliklich and Michelle Leavy collaborated on the development of the measures and co-authored the publication. The work was funded by the Agency for Healthcare Research and Quality (AHRQ) through[…]

OM1 Lupus Registry Reaches More Than 25,000 Patients Prospectively Followed With Deep Clinical And Lab Data

OM1 LUPUS REGISTRY REACHES MORE THAN 25,000 PATIENTS PROSPECTIVELY FOLLOWED WITH DEEP CLINICAL AND LAB DATA Ready for collaborations, the registry enables faster, more cost-effective access to research-grade lupus data for better understanding, comparing, and predicting treatment outcomes BOSTON, October 17, 2018 — OM1, a leading health outcomes, registries and technology company creating solutions to[…]

Using Big Data Like Biomarkers to Advance Clinical Development & Commercialization

March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]

Artificial Intelligence for Real-World Evidence

Published on HealthEconomics.com on January 3, 2018   As artificial intelligence (AI) and Big Data are lauded for their potential uses in life sciences and healthcare, it is becoming difficult to differentiate between the myriad of terms and technologies and their real value in advancing real-world evidence (RWE).   In this article, we explore key AI[…]